Source link : https://www.newshealth.biz/health-news/fda-panel-rejects-sglt1-2-inhibitor-for-type-1-diabetes/
An FDA panel on Thursday recommended against sotagliflozin as an adjunct to insulin for patients with type 1 diabetes (T1D) and mild-to-moderate chronic kidney disease (CKD). With a vote of 11-3, the Endocrinologic and Metabolic Drugs Advisory Committee said the benefits of the dual SGLT1/SGLT2 inhibitor do not outweigh the risks in this patient population, […]
Author : News Health
Publish date : 2024-11-01 17:50:57
Copyright for syndicated content belongs to the linked Source.